Ropes & Gray Guides Italy's Chiesi On $1.9B US Biotech Deal
Chiesi Group said Wednesday it will acquire KalVista Pharmaceuticals in a deal valued at about $1.9 billion, expanding the Italian biopharmaceutical company's rare disease portfolio with a newly approved treatment for...To view the full article, register now.
Already a subscriber? Click here to view full article